The earnings call highlighted significant clinical progress and strong revenue growth, especially with the early completion of the GTX-102 Phase III enrollment and the receipt of Breakthrough Therapy designation. However, these positives were tempered by financial losses and a regulatory setback with the UX111 CRL, indicating a balanced sentiment.

Company Guidance -

Q3 2025

During the Ultragenyx Second Quarter 2025 Financial Results Conference Call, the company provided updated guidance and key metrics for the year. Ultragenyx reported $306 million in total revenue for the first half of 2025, marking a 20% growth compared to the previous year, and they projected total revenue for 2025 to be between $640 million and $670 million. The company's flagship product, Crysvita, contributed $120 million in the second quarter, with a revenue expectation of $460 million to $480 million for the year. Other products like Dojolvi and Evkeeza also showed steady growth, contributing $23 million and $15 million, respectively, in the second quarter. Operating expenses for the quarter were $274 million, with a net loss of $115 million. The company reaffirmed its path to GAAP profitability by 2027 while managing expenses meticulously. Key clinical programs, such as UX143 for osteogenesis imperfecta and GTX-102 for Angelman syndrome, continue to progress, with significant milestones expected in the coming months.

Milestone Achievements in Clinical Programs

Ultragenyx completed enrollment ahead of schedule for the Phase III Aspire study for GTX-102 with 129 patients in 7 months, and the company received Breakthrough Therapy designation from the FDA for GTX-102. Additionally, the company has five Phase III clinical programs fully enrolled or at the BLA submission stage.

Strong Revenue Growth

Ultragenyx reported a 20% growth in total revenue for the first half of 2025 versus the prior year, with $306 million in revenue across the first two quarters. The company expects to deliver $640 million to $670 million in total revenue for the year.

Positive Commercial Performance

Crysvita, Dojolvi, Evkeeza, and Mepsevii continue to contribute to Ultragenyx's top line, with revenue for Crysvita expected to grow 12% to 17% over 2024.

Ultragenyx Pharmaceutical (RARE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RARE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	-1.24 / -	-1.4	―	―	―
Aug 05, 2025	2025 (Q2)	-1.30 / -1.17	-1.52	23.03% (+0.35)
May 06, 2025	2025 (Q1)	-1.60 / -1.57	-2.03	22.66% (+0.46)
Feb 13, 2025	2024 (Q4)	-1.31 / -1.39	-1.52	8.55% (+0.13)
Nov 05, 2024	2024 (Q3)	-1.48 / -1.40	-2.23	37.22% (+0.83)
Aug 01, 2024	2024 (Q2)	-1.66 / -1.52	-2.25	32.44% (+0.73)
May 02, 2024	2024 (Q1)	-1.75 / -2.03	-2.33	12.88% (+0.30)
Feb 15, 2024	2023 (Q4)	-1.71 / -1.52	-2.16	29.63% (+0.64)
Nov 02, 2023	2023 (Q3)	-2.08 / -2.23	-3.5	36.29% (+1.27)
Aug 03, 2023	2023 (Q2)	-2.09 / -2.25	-2.26	0.44% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RARE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$28.92	$28.05	-3.01%
May 06, 2025	$35.06	$33.42	-4.68%
Feb 13, 2025	$43.52	$42.49	-2.37%
Nov 05, 2024	$52.18	$50.52	-3.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ultragenyx Pharmaceutical (RARE) report earnings?

Ultragenyx Pharmaceutical (RARE) is schdueled to report earning on Nov 04, 2025, TBA (Confirmed).

What is Ultragenyx Pharmaceutical (RARE) earnings time?

Ultragenyx Pharmaceutical (RARE) earnings time is at Nov 04, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RARE EPS forecast?

RARE EPS forecast for the fiscal quarter 2025 (Q3) is -1.24.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing